|
Jun 2
|
Gilead Reports Positive Data From Trodelvy, Keytruda Combo Study
|
|
Jun 1
|
Kite Presents New Real-World Data Supporting Use of Potentially Curative Yescarta® in Outpatient Care Setting for Patients with Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025
|
|
May 31
|
Gilead's Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trial
|
|
May 31
|
Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer
|
|
May 30
|
Gilead Sciences Stock Gains 21% YTD: Buy, Sell or Hold?
|
|
May 30
|
Gilead Sciences Commemorated the Opening of the Bay Area Young Survivors Breast Cancer Memorial Garden
|
|
May 29
|
Why Is Repligen (RGEN) Down 12.2% Since Last Earnings Report?
|
|
May 29
|
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
|
|
May 23
|
Gilead Sciences (NasdaqGS:GILD) Announces Promising Phase 3 Results For Trodelvy In Breast Cancer
|
|
May 23
|
Gilead (GILD) to Acquire HOOK for $10 million
|
|
May 23
|
ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors
|
|
May 21
|
Here's Why Gilead Sciences (GILD) is a Strong Value Stock
|
|
May 20
|
Gilead Sciences vs GSK: Which HIV Drugmaker is a Smarter Buy Now?
|
|
May 18
|
Gilead Sciences, Inc. (GILD) and Kite to Present Breakthrough Cancer Therapy Data at 2025 ASCO and EHA
|
|
May 1
|
Gilead Sciences' (NASDAQ:GILD) Performance Is Even Better Than Its Earnings Suggest
|
|
Apr 30
|
Should You Buy, Sell or Hold GILD Stock Post Q1 Earnings Miss?
|
|
Apr 30
|
Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?
|
|
Apr 29
|
Sector Update: Health Care Stocks Gain Late Afternoon
|
|
Apr 29
|
Update: Gilead Sciences to Pay $202 Million in Settlement of Illegal Kickbacks Lawsuit
|
|
Apr 29
|
Gilead Sciences (NasdaqGS:GILD) Showcases Promising Liver Disease Treatments At EASL Congress
|